Enhancing the Effects of Anti-Cancer Drug ICRF-193
Casein kinase II (CKII) phosphorylates DNA topoisomerase II (topo II), thus activating the ATPase domain of the enzyme (left). This activation cancels the effects of anti-cancer drug ICRF-193. If CKII activity is attenuated (right), the efficacy of ICRF-193 is rescued. The G0 Cell Unit demonstrated this mechanism in fission yeast, a simple model that could be used for anti-cancer drug screening.
Free for anyone to re-use, but must be credited to OIST.
This work is licensed under a Creative Commons Attribution 2.0 Generic License.